|
(Natural News) The title was sure and clear, an eye-catcher: “Ivermectin flops again for COVID. This time in high-risk adults.” Even the subtitle was definitive, authoritative: “Malaysian trial finds no difference in progression to severe disease over standard of care.” Coming from a medical news website, MedPage Today, the article should be enough to convince… |